Huh Kyungmin, Ji Wonjun, Kang Minsun, Hong Jinwook, Bae Gi Hwan, Lee Rugyeom, Na Yewon, Jung Jaehun
Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06351, South Korea.
Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, South Korea.
Int J Infect Dis. 2021 Mar;104:7-14. doi: 10.1016/j.ijid.2020.12.041. Epub 2020 Dec 19.
Concerns have been expressed that some drugs may increase susceptibility to SARS-CoV-2 infection. In contrast, other drugs have generated interest as potential therapeutic agents.
All adults aged ≥18 years who were tested for COVID-19 were included. Exposure was defined as a prescription of study drugs which would have been continued until 7 days prior to test for COVID-19 or later. The outcome measures were the diagnosis of COVID-19 and severe COVID-19. Disease risk score matching and multiple logistic regression was used.
Matched claims and testing results were available for 219,961 subjects, of whom 7,341 (3.34%) were diagnosed with COVID-19. Patients were matched to 36,705 controls, and the subset of 878 patients of severe COVID-19 also matched with 1,927 mild-to-moderate patients. Angiotensin receptor blockers were not associated with either the diagnosis of COVID-19 (adjusted OR [aOR], 1.02; 95% confidence interval [CI], 0.90-1.15) or severe disease (aOR, 1.11; 95% CI, 0.87-1.42). The use of hydroxychloroquine was not associated with a lower risk for COVID-19 (aOR, 0.94; 95% CI, 0.53-1.66) or severe disease (aOR, 3.51; 95% CI, 0.76-16.22).
In this national claims data-based case-control study, no commonly prescribed medications were associated with risk of COVID-19 infection or COVID-19 severity.
有人担心某些药物可能会增加对SARS-CoV-2感染的易感性。相比之下，其他药物作为潜在治疗剂引起了人们的兴趣。
纳入所有接受过COVID-19检测的18岁及以上成年人。暴露定义为研究药物的处方，该药物会持续使用至COVID-19检测前7天或更晚。结局指标为COVID-19诊断和重症COVID-19。采用疾病风险评分匹配和多重逻辑回归分析。
获得了219,961名受试者的匹配索赔和检测结果，其中7341人（3.34%）被诊断为COVID-19。患者与36,705名对照进行匹配，878名重症COVID-19患者的子集也与1927名轻至中度患者进行匹配。血管紧张素受体阻滞剂与COVID-19诊断（校正比值比[aOR]，1.02；95%置信区间[CI]，0.90-1.15）或重症疾病（aOR，1.11；95%CI，0.87-1.42）均无关。使用羟氯喹与COVID-19风险降低（aOR，0.94；95%CI，0.53-1.66）或重症疾病（aOR，3.51；95%CI，0.76-16.22）均无关。
在这项基于全国索赔数据的病例对照研究中，没有常用处方药与COVID-19感染风险或COVID-19严重程度相关。
